RO 6958948

Drug Profile

RO 6958948

Alternative Names: 18F-labelled RO 6958948; [18F]RO 6958948; RO6958948

Latest Information Update: 20 Sep 2016

Price : $50

At a glance

  • Originator Roche
  • Class Imaging agents; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 01 Jul 2016 Roche initiates a phase I follow-up trial in Alzheimer's disease (Diagnosis) in USA (NCT02792179)
  • 02 Jun 2016 Roche plans a phase I follow-up trial in Alzheimer's disease (Diagnosis) in USA (NCT02792179)
  • 01 Aug 2014 Phase-I clinical trials in Alzheimer's disease (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top